FI971314A - Uusia androstaaneja hypotalamisten vaikutusten aikaansaamiseksi - Google Patents

Uusia androstaaneja hypotalamisten vaikutusten aikaansaamiseksi Download PDF

Info

Publication number
FI971314A
FI971314A FI971314A FI971314A FI971314A FI 971314 A FI971314 A FI 971314A FI 971314 A FI971314 A FI 971314A FI 971314 A FI971314 A FI 971314A FI 971314 A FI971314 A FI 971314A
Authority
FI
Finland
Prior art keywords
androstanes
produce
new
hypothalamic effects
hypothalamic
Prior art date
Application number
FI971314A
Other languages
English (en)
Swedish (sv)
Other versions
FI971314A0 (fi
Inventor
David L Berliner
Nathan William Adams
Clife L Jennings-White
Original Assignee
Pherin Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pherin Corp filed Critical Pherin Corp
Publication of FI971314A0 publication Critical patent/FI971314A0/fi
Publication of FI971314A publication Critical patent/FI971314A/fi

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J1/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, not substituted in position 17 beta by a carbon atom, e.g. estrane, androstane
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/568—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/02—Drugs for disorders of the endocrine system of the hypothalamic hormones, e.g. TRH, GnRH, CRH, GRH, somatostatin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J1/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, not substituted in position 17 beta by a carbon atom, e.g. estrane, androstane
    • C07J1/0003—Androstane derivatives
    • C07J1/0007—Androstane derivatives not substituted in position 17
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J1/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, not substituted in position 17 beta by a carbon atom, e.g. estrane, androstane
    • C07J1/0003—Androstane derivatives
    • C07J1/0033—Androstane derivatives substituted in position 17 alfa and 17 beta
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J1/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, not substituted in position 17 beta by a carbon atom, e.g. estrane, androstane
    • C07J1/0051—Estrane derivatives
    • C07J1/0055—Estrane derivatives not substituted in position 17
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J13/00—Normal steroids containing carbon, hydrogen, halogen or oxygen having a carbon-to-carbon double bond from or to position 17
    • C07J13/002—Normal steroids containing carbon, hydrogen, halogen or oxygen having a carbon-to-carbon double bond from or to position 17 with double bond in position 13 (17)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J13/00—Normal steroids containing carbon, hydrogen, halogen or oxygen having a carbon-to-carbon double bond from or to position 17
    • C07J13/005—Normal steroids containing carbon, hydrogen, halogen or oxygen having a carbon-to-carbon double bond from or to position 17 with double bond in position 16 (17)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J13/00—Normal steroids containing carbon, hydrogen, halogen or oxygen having a carbon-to-carbon double bond from or to position 17
    • C07J13/007—Normal steroids containing carbon, hydrogen, halogen or oxygen having a carbon-to-carbon double bond from or to position 17 with double bond in position 17 (20)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J3/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, substituted in position 17 beta by one carbon atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J31/00—Normal steroids containing one or more sulfur atoms not belonging to a hetero ring
    • C07J31/006—Normal steroids containing one or more sulfur atoms not belonging to a hetero ring not covered by C07J31/003
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J41/00—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
    • C07J41/0005—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring the nitrogen atom being directly linked to the cyclopenta(a)hydro phenanthrene skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J71/00—Steroids in which the cyclopenta(a)hydrophenanthrene skeleton is condensed with a heterocyclic ring
    • C07J71/0005—Oxygen-containing hetero ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J75/00—Processes for the preparation of steroids in general
    • C07J75/005—Preparation of steroids by cyclization of non-steroid compounds
FI971314A 1994-09-29 1997-03-27 Uusia androstaaneja hypotalamisten vaikutusten aikaansaamiseksi FI971314A (fi)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/316,435 US5969168A (en) 1991-01-07 1994-09-29 Androstanes for inducing hypothalamic effects
PCT/US1995/012538 WO1996010031A1 (en) 1994-09-29 1995-09-29 Novel androstanes for inducing hypothalamic effects

Publications (2)

Publication Number Publication Date
FI971314A0 FI971314A0 (fi) 1997-03-27
FI971314A true FI971314A (fi) 1997-03-27

Family

ID=23229039

Family Applications (1)

Application Number Title Priority Date Filing Date
FI971314A FI971314A (fi) 1994-09-29 1997-03-27 Uusia androstaaneja hypotalamisten vaikutusten aikaansaamiseksi

Country Status (17)

Country Link
US (1) US5969168A (fi)
EP (1) EP0783512A4 (fi)
JP (1) JPH10509692A (fi)
KR (1) KR970706296A (fi)
CN (1) CN1057767C (fi)
AU (1) AU702704B2 (fi)
BR (1) BR9509173A (fi)
CA (1) CA2199043A1 (fi)
CZ (1) CZ92597A3 (fi)
FI (1) FI971314A (fi)
HU (1) HUT77665A (fi)
MX (1) MX9702252A (fi)
NO (1) NO971418L (fi)
NZ (1) NZ294508A (fi)
PL (1) PL319606A1 (fi)
RU (1) RU2160740C2 (fi)
WO (1) WO1996010031A1 (fi)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ257218A (en) * 1993-06-15 1998-07-28 Pherin Corp Androstane steroid-containing medicament for nasal administration
US6066627A (en) * 1994-08-04 2000-05-23 Pherin Corporation Steroids as neurochemical initiators of change in human blood levels of LH
CA2199044A1 (en) * 1994-09-29 1996-04-04 Pherin Corporation Novel estrenes for inducing hypothalamic effects
DE19509729A1 (de) * 1995-03-13 1996-09-19 Schering Ag 17-Difluormethylen-Estratriene
US5922699A (en) * 1996-06-07 1999-07-13 Pherin Corporation 19-nor-cholane steroids as neurochemical initiators of change in human hypothalamic function
AU726625B2 (en) * 1996-07-23 2000-11-16 Pherin Pharmaceuticals, Inc. Steroids as neurochemical stimulators of the VNO to alleviate symptoms of PMS and anxiety
US20030045514A1 (en) * 2001-05-03 2003-03-06 Louis Monti 17-Methyleneandrostan-3alpha-ol analogs as CRH inhibitors
US20040072814A1 (en) 2002-10-11 2004-04-15 Solvay Pharmaceuticals Gmbh Method for obtaining a natural mixture of conjugated equine estrogens depleted in non-conjugated lipophilic compounds
US8309539B2 (en) 2005-09-09 2012-11-13 Pherin Pharmaceuticals, Inc. Acute treatment of social phobia
CN112778390B (zh) * 2021-01-22 2022-09-30 厦门欧瑞捷生物科技有限公司 一种雄烯酮的合成方法

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2846451A (en) * 1953-12-11 1958-08-05 Syntex Sa Cyclopentanophenanthrene derivatives and process
US3043836A (en) * 1961-05-02 1962-07-10 Searle & Co 13beta-carboxy-17beta-hydroxy-10beta-methylgon-4-en-3-one, derivatives thereof and intermediates thereto
GB976215A (en) * 1962-03-15 1964-11-25 Searle & Co Improvements in or relating to steroids
US3264327A (en) * 1962-07-27 1966-08-02 Syntex Corp 17alpha-fluoro-, 17beta-chlorofluoroacetoxy- and 17beta-methyl-delta4-and delta5-androstene derivatives
US3281436A (en) * 1964-08-05 1966-10-25 Abbott Lab Process for making gem-difluorosteroids
US3413321A (en) * 1966-06-03 1968-11-26 Du Pont Selected 17-fluoro-delta16 steroids
US3470216A (en) * 1966-11-29 1969-09-30 Du Pont Selected 17,17-difluoro unsaturated androstanes
FR7725M (fi) * 1967-06-22 1970-03-02
US3681490A (en) * 1969-07-22 1972-08-01 Nat Res Dev Artificial insemination of pigs
DE2336432A1 (de) * 1973-07-13 1975-01-30 Schering Ag 3.17.18-trihydroxy-1.3.5(10)-oestratriene
FR2255313B1 (fi) * 1973-12-20 1976-10-08 Gole Jean
US4239681A (en) * 1974-04-15 1980-12-16 Richardson-Merrell Inc. Androst-4-en-19-ols
US4071625A (en) * 1974-05-13 1978-01-31 Richardson-Merrell Inc. 19-Oxygenated-5α-androstanes for the enhancement of libido
US4139617A (en) * 1974-05-13 1979-02-13 Richardson-Merrell Inc. 19-Oxygenated-androst-5-enes for the enhancement of libido
US4022769A (en) * 1974-05-13 1977-05-10 Richardson-Merrell Inc. Androst-4-en-19-ones
GB1550343A (en) * 1975-07-16 1979-08-15 Gist Brocades Nv Androstane derivatives
DE2758549A1 (de) * 1977-12-23 1979-07-05 Schering Ag Pharmazeutische zubereitung
US4133811A (en) * 1978-02-17 1979-01-09 E. R. Squibb & Sons, Inc. 13-Alkylthio (and arylthio)-11,17-epoxy-17-methyl-18-norandrostenes
US4212815A (en) * 1978-07-05 1980-07-15 E. I. Du Pont De Nemours And Company Preparation of vinylene fluorides
US4425339A (en) * 1981-04-09 1984-01-10 Syntex (U.S.A.) Inc. Treatment of menopausal symptoms
US4349474A (en) * 1981-07-27 1982-09-14 G. D. Searle & Co. 2-Cyanosteroids
US5155045A (en) * 1985-01-25 1992-10-13 Trustees Of The University Of Penn. Use of male essence to alter female endocrine response
US4863911A (en) * 1986-08-04 1989-09-05 University Of Florida Method for treating male sexual dysfunction
US4835147A (en) * 1987-05-06 1989-05-30 City Of Hope Dehydroepiandrosterone therapy for ameleoration of prostate hypertrophy and sexual dysfunction
CA2425841C (en) * 1991-11-22 2006-01-10 Alcon Laboratories, Inc. Angiostatic steroids
US5272134A (en) * 1992-03-24 1993-12-21 Erox Corporation Fragrance compositions and other compositions which contain human pheromones
NZ257218A (en) * 1993-06-15 1998-07-28 Pherin Corp Androstane steroid-containing medicament for nasal administration
CA2199044A1 (en) * 1994-09-29 1996-04-04 Pherin Corporation Novel estrenes for inducing hypothalamic effects

Also Published As

Publication number Publication date
KR970706296A (ko) 1997-11-03
EP0783512A1 (en) 1997-07-16
NO971418D0 (no) 1997-03-25
PL319606A1 (en) 1997-08-18
AU702704B2 (en) 1999-03-04
FI971314A0 (fi) 1997-03-27
US5969168A (en) 1999-10-19
RU2160740C2 (ru) 2000-12-20
CN1166836A (zh) 1997-12-03
CN1057767C (zh) 2000-10-25
NZ294508A (en) 1999-02-25
AU3732995A (en) 1996-04-19
EP0783512A4 (en) 1998-09-02
CA2199043A1 (en) 1996-04-04
HUT77665A (hu) 1998-07-28
MX9702252A (es) 1997-06-28
CZ92597A3 (en) 1997-09-17
NO971418L (no) 1997-05-23
JPH10509692A (ja) 1998-09-22
BR9509173A (pt) 1997-11-25
WO1996010031A1 (en) 1996-04-04

Similar Documents

Publication Publication Date Title
DE69603894T2 (de) Interferon-Lösung
DE69519507T2 (de) Produktionssystem
FI955312A0 (fi) Staurosporiinijohdannaisen intravenoosit liuokset
BR9508318A (pt) Composição impadora concentrada
FI971314A (fi) Uusia androstaaneja hypotalamisten vaikutusten aikaansaamiseksi
FI971315A (fi) Uusia estreenejä hypotalamisten vaikutusten aikaansaamiseksi
DE9415655U1 (de) Saugersystem
DE69500635D1 (de) Einpunkt Bondverfahren
DE9402973U1 (de) Tapete
DE9410831U1 (de) Fahrradluftpumpe
DE29521219U1 (de) Leitungskanal
FIU940156U0 (fi) Bladkonstruktion foer en innebandy-klubba eller motsvarande
DE69429650D1 (de) Neues antitumor-peptid
DE9411382U1 (de) Fahrrad-Luftpumpe
KR960026423U (ko) 인삼재배용 골재조립구조
KR960011651U (ko) 호스의 연결구조물
DE9413657U1 (de) Schindelblende
KR960008616U (ko) 폴리파이프와의 연결수단을 갖는 폴리밸브
FI943330A (fi) Järjestely hissin toimintatilan näyttämiseksi
SE9400371L (sv) Kompositioner för inhalation
FIU940540U0 (fi) Skyddsstycke foer att aostadkomma ett spaor i en vindruta eller motsvarande
FI941032A0 (fi) Saett att oeverfoera en sjoecontainer
KR950022793U (ko) 수지침관
KR950032253U (ko) 수지침관
ID16384A (id) Larutan interferon